SIRT3-KLF15 signaling ameliorates kidney injury induced by hypertension.

SIRT3-KLF15 signaling ameliorates kidney injury induced by hypertension.
复制标题

DOI:
10.18632/oncotarget.17165
复制
发表时间:
2017-06-13
期刊:
影响因子:
--
通讯作者:
Bu P
Bu P
中科院分区:
其他
文献类型:
--
作者:
Li N;Zhang J;Yan X;Zhang C;Liu H;Shan X;Li J;Yang Y;Huang C;Zhang P;Zhang Y;Bu P

文献摘要

参考文献

被引文献

相似文献

肾纤维化参与了高血压肾损伤的发展过程。SIRT3是NAD+依赖的脱乙酰酶家族的一员,其在高血压肾病中的作用尚不清楚。在本研究中,我们发现血管紧张素II(AngII)在体内和体外处理后,SIRT3均降低。此外,SIRT3基因敲除小鼠通过慢性血管紧张素Ⅱ输注(每分钟2000 ng/kg,持续42天)加重了高血压引起的肾功能障碍和肾脏纤维化。相反,与野生型小鼠相比,SIRT3过表达小鼠减轻了血管紧张素转换酶I诱导的肾脏损伤。值得注意的是,SIRT3和KLF15(一种富含肾脏的核转录因子)的共同定位导致SIRT3直接使KLF15去乙酰化,随后在培养的MPC-5足细胞中纤维连接蛋白和IV型胶原的表达减少。厚朴中的主要活性成分和厚朴酚(HKL)通过激活SIRT3-KLF15信号通路抑制Angii诱导的肾纤维化。综上所述,我们的研究结果表明,一个新的SIRT3-KLF15信号可能预防高血压引起的肾脏损伤,HKL可能作为SIRT3-KLF15信号激活剂来保护高血压肾病。
Renal fibrosis participates in the progression of hypertension-induced kidney injury. The effect of SIRT3, a member of the NAD+-dependent deacetylase family, in hypertensive nephropathy remains unclear. In this study, we found that SIRT3 was reduced after angiotensin II (AngII) treatment both in vivo and in vitro. Furthermore, SIRT3-knockout mice aggravated hypertension-induced renal dysfunction and renal fibrosis via chronic AngII infusion (2000 ng/kg per minute for 42 days). On the contrary, SIRT3-overexpression mice attenuated AngII-induced kidney injury compared with wild-type mice. Remarkably, a co-localization of SIRT3 and KLF15, a kidney-enriched nuclear transcription factor, led to SIRT3 directly deacetylating KLF15, followed by decreased expression of fibronectin and collagen type IV in cultured MPC-5 podocytes. In addition, honokiol (HKL), a major bioactive compound isolated from Magnolia officinalis (Houpo), suppressed AngII-induced renal fibrosis through activating SIRT3-KLF15 signaling. Taken together, our findings implicate that a novel SIRT3-KLF15 signaling may prevent kidney injury from hypertension and HKL can act as a SIRT3-KLF15 signaling activator to protect against hypertensive nephropathy.
DOI: 10.1042/cs20120190
发表时间: 2013-02
期刊: Clinical science (London, England : 1979)
影响因子: --
作者:
Kitada M;Kume S;Takeda-Watanabe A;Kanasaki K;Koya D
通讯作者: Koya D
DOI: 10.1038/ki.2015.273
发表时间: 2015-11
影响因子: 19.6
作者:
Andeen NK;Nguyen TQ;Steegh F;Hudkins KL;Najafian B;Alpers CE
通讯作者: Alpers CE
DOI: 10.3390/v7092852
发表时间: 2015-09-10
期刊: Viruses
影响因子: --
作者:
Fang CY;Chen SJ;Wu HN;Ping YH;Lin CY;Shiuan D;Chen CL;Lee YR;Huang KJ
通讯作者: Huang KJ
DOI: 10.1038/emm.2016.28
发表时间: 2016-05-13
影响因子: 12.8
作者:
Kim SH;Kim HJ;Kim CW
通讯作者: Kim CW
DOI: 10.1161/hypertensionaha.108.112706
发表时间: 2008-08-01
期刊: HYPERTENSION
影响因子: 8.3
作者:
Liao, Tang-Dong;Yang, Xiao-Ping;Carretero, Oscar A.
通讯作者: Carretero, Oscar A.